Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes

Cancer

Volumn 121, Issue 4, 2015, Pages 589-597

  Hallet, Julie ^a,b   Law, Calvin How Lim ^a,b   Cukier, Moises ^a,b   Saskin, Refik ^c   Liu, Ning ^c   Singh, Simron ^a,d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Carcinoid; Detection; Epidemiology; Incidence; Neuroendocrine

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANADA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; GENDER; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; POPULATION RESEARCH; PRIMARY TUMOR; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RURAL AREA; SURVIVAL RATE; FACTUAL DATABASE; INCIDENCE; KAPLAN MEIER METHOD; MORTALITY; NEUROENDOCRINE TUMORS; PATHOLOGY; POVERTY; RISK; RISK FACTOR; RURAL POPULATION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ODDS RATIO; ONTARIO; POVERTY; RETROSPECTIVE STUDIES; RISK FACTORS; RURAL POPULATION; TREATMENT OUTCOME;

EID: 84922553363     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29099     Document Type: Article

References (28)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
2. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-1751.
3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.
4. Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol. 2007;102:1464-1473.
5. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:691-703.
6. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-1289.
7. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
8. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
9. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311-4318.
10. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology. Cancer. 2008;113:2655-2664.
11. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105:2563-2569.
12. Zarate X, Williams N, Herrera MF. Pancreatic incidentalomas. Best Pract Res Clin Endocrinol Metab. 2012;26:97-103.
13. Institute for Clinical Evaluative Sciences. http://www.ices.on.ca. Accessed September 2014.
14. Health Canada. Canada Health Act. http://www.hc-sc.gc.ca/hcs-sss/medi-assur/cha-lcs/index-eng.php. Accessed January 2014.
15. Robles SC, Marrett LD, Clarke EA, Risch HA. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988;41:495-501.
16. Clarke EA, Marrett LD, Kreiger N. Cancer registration in Ontario: a computer approach. IARC Sci Publ. 1991:246-257.
17. Holowaty EJ, Dale D. The hospital-only project. Health Rep. 1993; 5:91-95.
18. Paszat LF, Brundage MD, Groome PA, Schulze K, Mackillop WJ. A population-based study of rectal cancer: permanent colostomy as an outcome. Radiat Oncol Biol. 1999;45:1185-1191.
19. World Health Organization. International Classification of Diseases for Oncology (ICD-O). Geneva, Switzerland: World Health Organization; 1976.
20. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death (9th Revision). Geneva, Switzerland: World Health Organization; 1977.
21. Wilkins R. Use of postal codes and addresses in the analysis of health data. Health Rep. 1993;5:157-177.
22. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One. 2013;8:e62487.
23. Westergaard T, Frisch M, Melbye M. Carcinoid tumors in Denmark 1978-1989 and the risk of subsequent cancers. A population-based study. Cancer. 1995;76:106-109.
24. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in the Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001;12:1295-1300.
25. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204-2210.
26. Feinberg Y, Law C, Singh S, Wright FC. Patient experiences of having a neuroendocrine tumour: a qualitative study. Eur J Oncol Nurs. 2013;17:541-545.
27. Teckle P, Hannaford P, Sutton M. Is the health of people living in rural areas different from those in cities? Evidence from routine data linked with the Scottish Health Survey. BMC Health Serv Res. 2012; 12:43.
28. Ohrvall U, Eriksson B, Juhlin C, et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg. 2000;24:1402-1408.